150 related articles for article (PubMed ID: 31775034)
1. IRF4 Activity Is Required in Established Plasma Cells to Regulate Gene Transcription and Mitochondrial Homeostasis.
Low MSY; Brodie EJ; Fedele PL; Liao Y; Grigoriadis G; Strasser A; Kallies A; Willis SN; Tellier J; Shi W; Gabriel S; O'Donnell K; Pitt C; Nutt SL; Tarlinton D
Cell Rep; 2019 Nov; 29(9):2634-2645.e5. PubMed ID: 31775034
[TBL] [Abstract][Full Text] [Related]
2. IRF4 in multiple myeloma-Biology, disease and therapeutic target.
Agnarelli A; Chevassut T; Mancini EJ
Leuk Res; 2018 Sep; 72():52-58. PubMed ID: 30098518
[TBL] [Abstract][Full Text] [Related]
3. Regulatory network of BLIMP1, IRF4, and XBP1 triad in plasmacytic differentiation and multiple myeloma pathogenesis.
Tang TF; Chan YT; Cheong HC; Cheok YY; Anuar NA; Looi CY; Gan GG; Wong WF
Cell Immunol; 2022 Oct; 380():104594. PubMed ID: 36081178
[TBL] [Abstract][Full Text] [Related]
4. IRF4 addiction in multiple myeloma.
Shaffer AL; Emre NC; Lamy L; Ngo VN; Wright G; Xiao W; Powell J; Dave S; Yu X; Zhao H; Zeng Y; Chen B; Epstein J; Staudt LM
Nature; 2008 Jul; 454(7201):226-31. PubMed ID: 18568025
[TBL] [Abstract][Full Text] [Related]
5. Hypoxia-inducible microRNA-210 regulates the DIMT1-IRF4 oncogenic axis in multiple myeloma.
Ikeda S; Kitadate A; Abe F; Saitoh H; Michishita Y; Hatano Y; Kawabata Y; Kitabayashi A; Teshima K; Kume M; Takahashi N; Tagawa H
Cancer Sci; 2017 Apr; 108(4):641-652. PubMed ID: 28164410
[TBL] [Abstract][Full Text] [Related]
6. Impact of hypoxia on the pathogenesis and therapy resistance in multiple myeloma.
Ikeda S; Tagawa H
Cancer Sci; 2021 Oct; 112(10):3995-4004. PubMed ID: 34310776
[TBL] [Abstract][Full Text] [Related]
7. IRF4 promotes cell proliferation by JNK pathway in multiple myeloma.
Zhang S; Xu J; Wu S; Wang R; Qu X; Yu W; Li J; Chen L
Med Oncol; 2013; 30(2):594. PubMed ID: 23666852
[TBL] [Abstract][Full Text] [Related]
8. Dissecting the impact of bromodomain inhibitors on the Interferon Regulatory Factor 4-MYC oncogenic axis in multiple myeloma.
Agnarelli A; Mitchell S; Caalim G; Wood CD; Milton-Harris L; Chevassut T; West MJ; Mancini EJ
Hematol Oncol; 2022 Aug; 40(3):417-429. PubMed ID: 35544413
[TBL] [Abstract][Full Text] [Related]
9. Transcription factor IRF4 regulates germinal center cell formation through a B cell-intrinsic mechanism.
Willis SN; Good-Jacobson KL; Curtis J; Light A; Tellier J; Shi W; Smyth GK; Tarlinton DM; Belz GT; Corcoran LM; Kallies A; Nutt SL
J Immunol; 2014 Apr; 192(7):3200-6. PubMed ID: 24591370
[TBL] [Abstract][Full Text] [Related]
10. PU.1 acts as tumor suppressor for myeloma cells through direct transcriptional repression of IRF4.
Ueno N; Nishimura N; Ueno S; Endo S; Tatetsu H; Hirata S; Hata H; Matsuoka M; Mitsuya H; Okuno Y
Oncogene; 2017 Aug; 36(31):4481-4497. PubMed ID: 28368411
[TBL] [Abstract][Full Text] [Related]
11. The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival.
Ohguchi H; Hideshima T; Bhasin MK; Gorgun GT; Santo L; Cea M; Samur MK; Mimura N; Suzuki R; Tai YT; Carrasco RD; Raje N; Richardson PG; Munshi NC; Harigae H; Sanda T; Sakai J; Anderson KC
Nat Commun; 2016 Jan; 7():10258. PubMed ID: 26728187
[TBL] [Abstract][Full Text] [Related]
12. DOT1L inhibition blocks multiple myeloma cell proliferation by suppressing IRF4-MYC signaling.
Ishiguro K; Kitajima H; Niinuma T; Ishida T; Maruyama R; Ikeda H; Hayashi T; Sasaki H; Wakasugi H; Nishiyama K; Shindo T; Yamamoto E; Kai M; Sasaki Y; Tokino T; Nakase H; Suzuki H
Haematologica; 2019 Jan; 104(1):155-165. PubMed ID: 30171029
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical detection of multiple myeloma 1/interferon regulatory factor 4 (MUM1/IRF-4) in canine plasmacytoma: comparison with CD79a and CD20.
Ramos-Vara JA; Miller MA; Valli VE
Vet Pathol; 2007 Nov; 44(6):875-84. PubMed ID: 18039900
[TBL] [Abstract][Full Text] [Related]
14. Global miRNA expression analysis identifies novel key regulators of plasma cell differentiation and malignant plasma cell.
Kassambara A; Jourdan M; Bruyer A; Robert N; Pantesco V; Elemento O; Klein B; Moreaux J
Nucleic Acids Res; 2017 Jun; 45(10):5639-5652. PubMed ID: 28459970
[TBL] [Abstract][Full Text] [Related]
15. IRF4: Immunity. Malignancy! Therapy?
Shaffer AL; Emre NC; Romesser PB; Staudt LM
Clin Cancer Res; 2009 May; 15(9):2954-61. PubMed ID: 19383829
[TBL] [Abstract][Full Text] [Related]
16. MMSET regulates expression of IRF4 in t(4;14) myeloma and its silencing potentiates the effect of bortezomib.
Xie Z; Bi C; Chooi JY; Chan ZL; Mustafa N; Chng WJ
Leukemia; 2015 Dec; 29(12):2347-54. PubMed ID: 26196464
[TBL] [Abstract][Full Text] [Related]
17. C-terminal binding protein 2 is a novel tumor suppressor targeting the MYC-IRF4 axis in multiple myeloma.
Cheung CHY; Cheng CK; Leung KT; Zhang C; Ho CY; Luo X; Kam AYF; Xia T; Wan TSK; Pitts HA; Chan NPH; Cheung JS; Wong RSM; Zhang XB; Ng MHL
Blood Adv; 2024 May; 8(9):2217-2234. PubMed ID: 38457926
[TBL] [Abstract][Full Text] [Related]
18. Zinc finger-IRF composite elements bound by Ikaros/IRF4 complexes function as gene repression in plasma cell.
Ochiai K; Kondo H; Okamura Y; Shima H; Kurokochi Y; Kimura K; Funayama R; Nagashima T; Nakayama K; Yui K; Kinoshita K; Igarashi K
Blood Adv; 2018 Apr; 2(8):883-894. PubMed ID: 29669755
[TBL] [Abstract][Full Text] [Related]
19. The Immunity-malignancy equilibrium in multiple myeloma: lessons from oncogenic events in plasma cells.
Perini T; Materozzi M; Milan E
FEBS J; 2022 Aug; 289(15):4383-4397. PubMed ID: 34117720
[TBL] [Abstract][Full Text] [Related]
20. Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo.
Morelli E; Leone E; Cantafio ME; Di Martino MT; Amodio N; Biamonte L; Gullà A; Foresta U; Pitari MR; Botta C; Rossi M; Neri A; Munshi NC; Anderson KC; Tagliaferri P; Tassone P
Leukemia; 2015 Nov; 29(11):2173-83. PubMed ID: 25987254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
